HOME >> MEDICINE >> NEWS
Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met

LINCOLNSHIRE, Ill. Takeda Global Research & Development Center (TGR&D) today announced that the company has submitted a New Drug Application (NDA) for an extended-release version of the combination medication ACTOplus met TM (pioglitazone HCl and metformin HCl) to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes. This new formulation (ACTOplus met XR) would allow for once-daily dosing, while ACTOplus met (immediate release) is already available, being marketed by Takeda Pharmaceuticals North America, Inc.

ACTOplus met is an oral medication that combines ACTOS (pioglitazone HCl), which directly targets insulin resistance a condition in which the body does not efficiently use the insulin it produces with metformin, which acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels.

The NDA submission represents yet another milestone for Takeda, following the FDA approval of ROZEREMTM(ramelteon).

"We are certainly proud of this NDA submission, and the ACTOS portfolio of products," said John Yates, M.D., president of TGR&D. "Not all patients are alike, especially in diabetes, and the addition of this new product would provide patients and their physicians with more options and greater flexibility, while continuing to provide the benefits of treatment with ACTOS." Extended-release metformin, one of the active ingredients in ACTOplus met XR, was developed by Andrx Corporation. Takeda Pharmaceutical Company Limited signed an agreement with Andrx Corporation covering extended-release metformin in December 2003.


'"/>


3-Apr-2006


Page: 1

Related medicine news :

1. Takeda responds to the FDA advisory committee recommendation
2. Takeda submits new drug application for combination type 2 diabetes medication
3. Sucampo Pharmaceuticals submits supplemental new drug application for Lubiprostone to treat IBS-C
4. Sucampo submits new drug application for lubiprostone
5. Brightening prospects of using fluorescent nanotubes in medical applications
6. Panbio files first patent application for Homogenous Assay Technology
7. LOral accepting applications for 2007 USA fellowships for Women in Science
8. NIH wrongly blamed for reduced success rate of grant applications
9. Magnet lab researcher exploring science behind commercial applications of liquid helium
10. Dalai Lama, top scientists to discuss science & clinical applications of meditation
11. Mechanism controlling DNA damage response has potential novel medical applications

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... Calif. (PRWEB) , ... September 01, 2020 , ... As ... “safe side”, the Cohn Health Institute has taken this time to expand ... celebration of its 30th Anniversary, the Cohn Health Institute will be relaunching its brand ...
(Date:8/31/2020)... ... 2020 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... Awareness Month (BCAM) and its international Light it Red for Lymphoma ...
(Date:8/31/2020)... NEW YORK (PRWEB) , ... August 31, 2020 , ... ... On September 1, Cerebral Palsy Alliance Research Foundation (CPARF) is thrilled to launch its ... cerebral palsy research. A fully virtual challenge, STEPtember meets everyone wherever they are at ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... to dental groups in the United States, today announced the grand opening of ... CA. , Patients will enjoy convenient hours, a comfortable office, and full-service ...
(Date:8/31/2020)... ... August 31, 2020 , ... In an effort to give back to ... 10 percent of each hotel room booked with a special new rate code to ... Indiana (RMHC-CNI) , effective immediately. Donations will be applied to any room type, ...
Breaking Medicine News(10 mins):
(Date:8/28/2020)... ... August 28, 2020 , ... Cano Health, LLC, a ... Florida and San Antonio is happy to announce that it has selected Tejano ... this capacity he will serve as community advisor, advertising talent, and creative consultant ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... announced the successful completion of their 2020 System and Organizational Controls (SOC) 1® ... interim assessment and MARS-E compliance assessment. These achievements reflect their long-standing commitment to ...
(Date:8/27/2020)... HILL, N.C. (PRWEB) , ... August 27, 2020 , ... ... professional football player and sleep apnea patient, is the company’s new spokesperson. , “In ... the football field. So, when I found the Bleep DreamPort it was a Bleeping ...
Breaking Medicine Technology:
Cached News: